Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2012

01.03.2012 | Original Article

The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure

verfasst von: Georg Goliasch, Aliasghar Khorsand, Matthias Schütz, Georgios Karanikas, Cesar Khazen, Heinz Sochor, Herwig Schmidinger, Michael Wolzt, Senta Graf

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cardiac contractility modulation (CCM) is a device-based therapy that involves delivery of nonexcitatory electrical signals resulting in improved ventricular function and a reversal of maladaptive cardiac fetal gene programmes. Our aim was to evaluate whether acute application of CCM leads to an increase in myocardial oxygen consumption (MVO2) in patients with chronic heart failure using 11C-acetate positron emission tomography (PET).

Methods

We prospectively enrolled 21 patients with severe heart failure. 11C-acetate PET was performed before and after activation of the CCM device. In 12 patients an additional stress study with dobutamine was performed.

Results

Under resting conditions, the values of myocardial blood flow (MBF), MVO2 and work metabolic index (WMI, reflecting myocardial efficiency) with the CCM device activated did not differ significantly from the values with the device deactivated. MBF was 0.81 ± 0.18 ml min−1 g−1 with the device off and 0.80 ± 0.15 ml min−1 g−1 with the device on (p = 0.818), MVO2 was 6.81 ± 1.69 ml/min/100 g with the device off and 7.15 ± 1.62 ml/min/100 g with the device on (p = 0.241) and WMI was 4.94 ± 1.14 mmHg ml/m2 with the device off and 5.21 ± 1.36 mmHg ml/m2 with the device on (p = 0.344). Under dobutamine stress, the values of MBF, MVO2 and WMI with the CCM device activated did not differ from the values with the device deactivated, but were significantly increased compared with the values obtained under resting conditions.

Conclusion

These results indicate that CCM does not induce increased MVO2, even under stress conditions.
Literatur
1.
Zurück zum Zitat Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20(6):421–8.PubMedCrossRef Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20(6):421–8.PubMedCrossRef
3.
Zurück zum Zitat Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388–442. doi:10.1093/eurheartj/ehn309.PubMedCrossRef Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388–442. doi:10.​1093/​eurheartj/​ehn309.PubMedCrossRef
4.
Zurück zum Zitat Stix G, Borggrefe M, Wolpert C, Hindricks G, Kottkamp H, Bocker D, et al. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J. 2004;25(8):650–5. doi:10.1016/j.ehj.2004.02.027.PubMedCrossRef Stix G, Borggrefe M, Wolpert C, Hindricks G, Kottkamp H, Bocker D, et al. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J. 2004;25(8):650–5. doi:10.​1016/​j.​ehj.​2004.​02.​027.PubMedCrossRef
5.
Zurück zum Zitat Lawo T, Borggrefe M, Butter C, Hindricks G, Schmidinger H, Mika Y, et al. Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. J Am Coll Cardiol. 2005;46(12):2229–36. doi:10.1016/j.jacc.2005.05.093.PubMedCrossRef Lawo T, Borggrefe M, Butter C, Hindricks G, Schmidinger H, Mika Y, et al. Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. J Am Coll Cardiol. 2005;46(12):2229–36. doi:10.​1016/​j.​jacc.​2005.​05.​093.PubMedCrossRef
6.
Zurück zum Zitat Borggrefe MM, Lawo T, Butter C, Schmidinger H, Lunati M, Pieske B, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29(8):1019–28.PubMedCrossRef Borggrefe MM, Lawo T, Butter C, Schmidinger H, Lunati M, Pieske B, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29(8):1019–28.PubMedCrossRef
7.
8.
Zurück zum Zitat Imai M, Rastogi S, Gupta RC, Mishra S, Sharov VG, Stanley WC, et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol. 2007;49(21):2120–8. doi:10.1016/j.jacc.2006.10.082.PubMedCrossRef Imai M, Rastogi S, Gupta RC, Mishra S, Sharov VG, Stanley WC, et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol. 2007;49(21):2120–8. doi:10.​1016/​j.​jacc.​2006.​10.​082.PubMedCrossRef
9.
Zurück zum Zitat Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation. 1986;73(3 Pt 2):184–90. Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation. 1986;73(3 Pt 2):184–90.
10.
Zurück zum Zitat Christenson SD, Chareonthaitawee P, Burnes JE, Hill MR, Kemp BJ, Khandheria BK, et al. Effects of simultaneous and optimized sequential cardiac resynchronization therapy on myocardial oxidative metabolism and efficiency. J Cardiovasc Electrophysiol. 2008;19(2):125–32.PubMedCrossRef Christenson SD, Chareonthaitawee P, Burnes JE, Hill MR, Kemp BJ, Khandheria BK, et al. Effects of simultaneous and optimized sequential cardiac resynchronization therapy on myocardial oxidative metabolism and efficiency. J Cardiovasc Electrophysiol. 2008;19(2):125–32.PubMedCrossRef
11.
Zurück zum Zitat Ukkonen H, Beanlands RS, Burwash IG, de Kemp RA, Nahmias C, Fallen E, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation. 2003;107(1):28–31.PubMedCrossRef Ukkonen H, Beanlands RS, Burwash IG, de Kemp RA, Nahmias C, Fallen E, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation. 2003;107(1):28–31.PubMedCrossRef
12.
Zurück zum Zitat Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol. 1993;22(5):1389–98.PubMedCrossRef Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol. 1993;22(5):1389–98.PubMedCrossRef
13.
Zurück zum Zitat Beanlands RS, Nahmias C, Gordon E, Coates G, DeKemp R, Firnau G, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation. 2000;102(17):2070–5.PubMed Beanlands RS, Nahmias C, Gordon E, Coates G, DeKemp R, Firnau G, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation. 2000;102(17):2070–5.PubMed
14.
Zurück zum Zitat Porenta G, Cherry S, Czernin J, Brunken R, Kuhle W, Hashimoto T, et al. Noninvasive determination of myocardial blood flow, oxygen consumption and efficiency in normal humans by carbon-11 acetate positron emission tomography imaging. Eur J Nucl Med. 1999;26(11):1465–74.PubMedCrossRef Porenta G, Cherry S, Czernin J, Brunken R, Kuhle W, Hashimoto T, et al. Noninvasive determination of myocardial blood flow, oxygen consumption and efficiency in normal humans by carbon-11 acetate positron emission tomography imaging. Eur J Nucl Med. 1999;26(11):1465–74.PubMedCrossRef
15.
Zurück zum Zitat Khorsand A, Graf S, Frank H, Kletter K, Sochor H, Maurer G, et al. Model-based analysis of electrocardiography-gated cardiac (18)F-FDG PET images to assess left ventricular geometry and contractile function. J Nucl Med. 2003;44(11):1741–6.PubMed Khorsand A, Graf S, Frank H, Kletter K, Sochor H, Maurer G, et al. Model-based analysis of electrocardiography-gated cardiac (18)F-FDG PET images to assess left ventricular geometry and contractile function. J Nucl Med. 2003;44(11):1741–6.PubMed
16.
Zurück zum Zitat Kitaizumi K, Yukiiri K, Masugata H, Takinami H, Iwado Y, Noma T, et al. Acute improvement of cardiac efficiency measured by 11C-acetate PET after cardiac resynchronization therapy and clinical outcome. Int J Cardiovasc Imaging. 2010;26(3):285–92. doi:10.1007/s10554-009-9549-8.PubMedCrossRef Kitaizumi K, Yukiiri K, Masugata H, Takinami H, Iwado Y, Noma T, et al. Acute improvement of cardiac efficiency measured by 11C-acetate PET after cardiac resynchronization therapy and clinical outcome. Int J Cardiovasc Imaging. 2010;26(3):285–92. doi:10.​1007/​s10554-009-9549-8.PubMedCrossRef
17.
Zurück zum Zitat Butter C, Wellnhofer E, Schlegl M, Winbeck G, Fleck E, Sabbah HN. Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associated with increased myocardial oxygen consumption. J Card Fail. 2007;13(2):137–42. doi:10.1016/j.cardfail.2006.11.004.PubMedCrossRef Butter C, Wellnhofer E, Schlegl M, Winbeck G, Fleck E, Sabbah HN. Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associated with increased myocardial oxygen consumption. J Card Fail. 2007;13(2):137–42. doi:10.​1016/​j.​cardfail.​2006.​11.​004.PubMedCrossRef
Metadaten
Titel
The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure
verfasst von
Georg Goliasch
Aliasghar Khorsand
Matthias Schütz
Georgios Karanikas
Cesar Khazen
Heinz Sochor
Herwig Schmidinger
Michael Wolzt
Senta Graf
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1977-8

Weitere Artikel der Ausgabe 3/2012

European Journal of Nuclear Medicine and Molecular Imaging 3/2012 Zur Ausgabe